Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5985659 | 0.79 | — | — | |
| SCHEMBL16347471 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRDNM1SMN1; SMN2 | |
| SCHEMBL2120964 | 0.78 | — | — | |
| SCHEMBL8706560 | 0.75 | — | — | |
| SCHEMBL12475459 | 0.72 | — | — | |
| SCHEMBL3671291 | 0.72 | — | — | |
| SCHEMBL5984488 | 0.72 | — | — | |
| SCHEMBL2118765 | 0.71 | OPRM1 (0.42) | DNM1CA1 | |
| SCHEMBL231722 | 0.70 | — | — | |
| SCHEMBL15759 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | claimed |
| EP-4392420-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-3835298-B1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12011445-B2 | Prevention of pancreatic cell degeneration | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4366833-A1 | CANCER THERAPEUTICS | Universitat de Barcelona (ES) | 2024-05-15 | — | — | EP | disclosed |
| EP-4359422-A1 | A NOVEL COMPOUND ACTING AGAINST A SELECT GROUP OF BACTERIA | NORTHEASTERN UNIVERSITY (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117957239-A | Cancer therapeutic agent | 巴塞罗那大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20240132502-A1 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2002043765-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING PACLITAXEL, DERIVATIVES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSFORM PHARMACEUTICALS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1204626-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Esperion Therapeutics Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| US-20020045639-A1 | COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT | US ARMY, SECRETARY OF THE ARMY | 2002-04-18 | — | — | US | disclosed |
| WO-2002030882-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6369052-B1 | REVERSE NEURONAL DYSFUNCTION; ALZHEIMER'S; PARKINSON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; STROKES; SPINAL-CORD AND PERIPHERAL NERVE INJURIES; TRANSDERMAL PATCH. | GEORGETOWN UNIVERSITY | 2002-04-09 | — | — | US | disclosed |
| WO-2002011712-A2 | COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT | GEORGETOWN UNIVERSITY (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132502-A1 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | BTK, LYN, SYK | ALDH1A1 4009/4885TDP1 176/4885TSHR 2496/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | ALDH1A1 2636/4885TDP1 1304/4885TSHR 1980/4885 |
| US-20020045639-A1 | COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT | CHRNA5, CHRNA4, CHRNA2 | ALDH1A1 2500/4885TDP1 266/4885TSHR 4224/4885 |
| US-12011445-B2 | Prevention of pancreatic cell degeneration | IAPP, AMY2A, PNLIP | ALDH1A1 633/4885TDP1 757/4885TSHR 3378/4885 |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | SOS1, SOS2, IQGAP1 | ALDH1A1 3135/4885TDP1 1004/4885TSHR 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.